PTGS2 and neoplasm: Zhang designed an MCNCD nanoparticle carrying a nonsteroidal anti-inflammatory drug (celecoxib) to inhibit cyclooxygenase-2 (COX-2) from disrupting the PG2I/TXA2 balance, ultimately inducing intravascular thrombosis and reducing the risk of tumor metastasis after PTT treatment.